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Statement of translational relevance   
The phosphoinositide 3-kinase (PI3K) signaling pathway is frequently dysregulated in 
human cancer and activating mutations in PIK3CA (encoding the p110α catalytic subunit 
of PI3Kα) are strongly implicated in oncogenic PI3K signaling. In addition, activation of 
PI3K pathway has also been implicated as a tumor cell survival mechanism in response to 
chemotherapy. PI3Kα-selective inhibitors, versus pan-PI3K pathway inhibitors, should 
provide more specific inhibition of PI3Kα while minimizing the side effects caused by non-
selective blockade of other PI3K isoforms. This first-in-human phase I study investigated 
TAK-117, a potent and selective oral PI3Kα isoform inhibitor, in adult patients with 
advanced solid tumors. TAK-117 demonstrated an acceptable safety profile at the 
maximum tolerated doses and preliminary evidence of single-agent antitumor activity in 
this study. Additionally, results showed that intermittent dosing of TAK-117 (3 days per 
week) had improved tolerability versus continuous daily dosing of TAK-117. Intermittent 
TAK-117 dosing resulted in fewer transaminase elevations versus QD dosing and allowed 
for higher dose levels (thus, higher total weekly doses and exposure). This high-dose 
intermittent schedule may allow TAK-117 to be combined with other antitumor therapies, to 
effectively block the PI3K pathway activation that is a part of the adaptive survival 
mechanism of tumor cells following exposure to cellular stress and insults introduced by 
other drugs.  
Research. 
on November 1, 2017. © 2017 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 10, 2017; DOI: 10.1158/1078-0432.CCR-16-2888 
Phase I trial of the PI3Kα isoform inhibitor TAK-117 
Juric CCR-16-2888 Manuscript Revisions – 7 
Abstract  
Purpose: To evaluate the safety, maximum tolerated dose (MTD), pharmacokinetics, 
pharmacodynamics, and preliminary antitumor activity of TAK-117 (MLN1117/INK1117), 
an investigational PI3Kα-selective inhibitor, in patients with advanced solid tumors.  
Experimental Design: Seventy-one patients received oral TAK-117 once daily (QD, 100–
300 mg [n = 24]), or 3 days per week (Mon–Wed–Fri [MWF], 200–1200 mg [n = 27]; Mon–
Tue–Wed [MTuW], 200–900 mg [n = 20]), in 21-day cycles. Dose escalation proceeded 
via a 3+3 design. 
Results: TAK-117 QD dosing was associated with dose-limiting grade ≥3 
alanine/aspartate aminotransferase (ALT/AST) elevations, resulting in a narrow range of 
tolerable doses (100–150 mg QD). With MWF/MTuW dosing, no dose-limiting ALT/AST 
elevations occurred until the MTD of 900 mg; total weekly dose was 2.6-fold that of 150 
mg QD. Drug-related grade ≥3 adverse events occurred in 25%/22%/35% (including 
hyperglycemia in 0%/7%/15%) of QD/MWF/MTuW patients. TAK-117 (100–1200 mg) 
exhibited moderately fast oral absorption, a generally dose-proportional increase in 
exposure, and plasma half-life of ~11 hours. Total weekly exposures with 900 mg 
MWF/MTuW dosing were ~four times greater than with 150 mg QD. Skin pS6 expression 
was suppressed at ≥200 mg. There were 3/1/0 partial responses (QD/MWF/MTuW) and 
5/7/5 patients had stable disease lasting ≥3 months (all PIK3CA mutated). 
Conclusion: Intermittent dosing of TAK-117 had an acceptable safety profile and enabled 
higher doses and total weekly exposures versus QD dosing. While the potential for TAK-
117 as single-agent therapy appears limited, further evaluation in combination approaches 
for advanced solid tumors is warranted. 
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Introduction 
The phosphoinositide 3-kinase (PI3K) pathway is a frequently dysregulated signaling 
cascade in human cancer (1, 2). Activating mutations in PIK3CA (encoding the p110α 
catalytic subunit of PI3Kα) are strongly implicated in oncogenic PI3K signaling (2-4). The 
high frequency of PIK3CA mutations (~5% to 25% of solid tumors) suggests a therapeutic 
role for PI3Kα inhibitors in tumors driven by PI3K pathway activation (4-7). While several 
non-selective class I PI3K (pan-PI3K) pathway inhibitors are in development (8-15), in 
theory, PI3Kα-selective inhibitors should provide more specific inhibition of PI3Kα while 
minimizing the side effects caused by non-selective blockade of other PI3K isoforms. A 
higher selectivity, wider therapeutic window, and potentially improved benefit/risk profile 
would also provide opportunities for combining PI3Kα-selective inhibitors with other 
therapies. 
TAK-117 (MLN1117/INK1117) is a potent and selective oral PI3Kα isoform inhibitor 
(IC50 of 21 nM against PI3Kα) that has demonstrated >100-fold selectivity relative to other 
class I PI3K family members (PI3Kβ/γ/δ) and mTOR, and a high degree of selectivity 
against many other kinases. TAK-117 administration in PIK3CA-mutant tumor cell lines 
resulted in potent PI3K pathway inhibition, blockade of cellular proliferation, and apoptosis 
(16). Administration of TAK-117 also led to dose-dependent inhibition of tumor growth in 
murine xenograft models of human cancer (e.g., breast carcinoma) bearing PIK3CA 
oncogenic mutations, with corresponding inhibition of PI3K pharmacodynamic markers in 
tumor tissue (16). Preclinical anti-tumor activity of single-agent TAK-117 has been shown 
to be independent of dosing schedules and driven by total plasma exposures (17, 18). 
Conversely, TAK-117 was not efficacious in tumor models harboring PTEN and/or KRAS 
mutations (16). Preclinical studies showed TAK-117 to have low potential for disrupting 
glucose metabolism or for causing cardiac adverse events; in rats and monkeys, doses up 
to 50 mg/kg/day were well tolerated. 
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This phase I study of TAK-117 (NCT01449370) aimed to determine the maximum 
tolerated dose (MTD) and/or optimal biologic dose and dose-limiting toxicities (DLTs) when 
administered on a continuous daily (QD) or intermittent dosing schedule to patients with 
advanced solid tumors and known PIK3CA mutation status. Further objectives were to 
investigate safety/tolerability, pharmacokinetics, pharmacodynamics, and preliminary 
single-agent antitumor activity. 
 
Patients and methods 
Study design 
This phase I dose-escalation study evaluated three dosing schedules of oral TAK-
117 – QD or intermittent (Monday, Wednesday, Friday [MWF] or Monday, Tuesday, 
Wednesday [MTuW]) dosing in 21-day cycles until disease progression or unacceptable 
toxicities. TAK-117 was administered as capsules on an empty stomach, at approximately 
the same time each dosing day. Dose escalation followed a modified 3+3 design for all 
three dosing schedules. Dose-escalation and dose-modification guidelines are available in 
the Appendix. 
The study was conducted in accordance with the Declaration of Helsinki and Good 
Clinical Practice. Institutional review boards approved all aspects of the study. All 
participants provided written informed consent. 
Patients 
Eligible patients were ≥18 years old, had locally advanced or metastatic solid 
tumors (excluding primary brain tumors) with evidence of disease progression per 
Response Evaluation Criteria in Solid Tumors [RECIST] v1.1 (19), had failed or were not 
eligible for standard-of-care therapy, had an Eastern Cooperative Oncology Group 
performance status of 0–1, and adequate organ function (Appendix). Prior assessment of 
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tumor PIK3CA mutation status was a requirement for study enrollment. This was 
performed by means of local testing, using archival tissue samples. Patients were eligible 
to enter the study regardless of the presence or absence of PIK3CA mutations. Once 
enrolled, all patients who received at least 1 dose of TAK-117 had their PIK3CA mutation 
status re-assessed at a central laboratory. 
Assessments 
The primary objective was determination of TAK-117 MTDs for daily and 
intermittent dosing schedules. The MTD was defined as the highest dose level at which no 
more than one DLT occurred during cycle 1 in a minimum of 6 patients. DLTs are defined 
as any of the following toxicities, provided that they were considered to be related to TAK-
117 and that they occurred in cycle 1 (i.e., the first 21 days) following the patient’s first 
administration of TAK-117: 
• Grade 3 nausea and/or vomiting, or diarrhea lasting >7 days despite optimal 
treatment 
• Grade 2 fasting hyperglycemia lasting >14 days despite optimal treatment, or grade 
3 fasting hyperglycemia lasting >24 hours despite optimal treatment 
• Grade 3 rash lasting >7 days despite optimal treatment (all subjects could receive 
topical steroid treatment, oral antihistamines, and pulse oral steroids, if necessary) 
• Other grade ≥3 non-hematologic toxicity considered clinically significant by the 
investigator 
• Grade 3 thrombocytopenia with bleeding 
• Grade 4 neutropenia (absolute neutrophil count ≤500) lasting > 7 days in the 
absence of growth factor support 
• Grade 4 neutropenia of any duration associated with fever ≥38.5°C and/or systemic 
infection 
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• Any other grade ≥4 hematologic toxicity 
• Inability to administer ≥75% of the planned doses of TAK-117 within cycle 1 due to 
drug-related toxicity 
• Any clinically significant occurrence that the investigators and sponsor agreed 
would place patients at an undue safety risk. 
 
Safety was assessed throughout the study and according to National Cancer 
Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03. Antitumor 
activity was evaluated every 3 cycles according to RECIST v1.1. Blood samples were 
collected on day 1 at the following timepoints: pre-dose (within 1 hour), 0.5, 1, 2, 4, and 8 
hours post-dose, at 24 ± 2 hours post-dose (pre-dose on day 2), and at 48 ± 3 hours post-
dose (pre-dose on day 3; MWF only); additional sampling timepoints are described in the 
Appendix. The plasma concentration of TAK-117 was measured using liquid 
chromatography mass spectrometry with an assay range of 1 to 1000 ng/mL. TAK-117 
pharmacodynamics were evaluated via immunohistochemical analysis of phosphorylated 
S6 (pS6) expression at Ser235/236 in formalin-fixed paraffin-embedded sections of skin 
and tumor tissues. Skin biopsies from all patients and tumor biopsies from a subset of 
patients (who signed optional consent) were collected at screening and within 2–4 hours 
after dosing in week 2 of cycle 1 (QD dosing) or on day 1 of cycle 2 (intermittent dosing). A 
histochemical score (H-score) was assigned to each sample based on levels and areas of 
pS6 expression in the epidermis of a skin sample or tumor sample section as described 
previously (20). 
Statistical methods 
Patients evaluated for safety had received ≥1 dose of TAK-117. Response-
evaluable patients had received ≥1 dose of TAK-117 and had ≥1 post-treatment response 
assessment. DLT-evaluable patients included those who either experienced a DLT, or 
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received ≥75% of the planned TAK-117 doses in cycle 1 and were viewed by the sponsor 
and investigators to have adequate safety data to conclude that no DLTs occurred in cycle 
1. Pharmacokinetics-evaluable patients had received ≥1 dose of TAK-117 and had 
sufficient concentration–time data to calculate ≥1 pharmacokinetic parameter. 
Antitumor activity was assessed by summarizing the objective response rate (ORR; 
complete response plus partial response [PR]) and clinical benefit rate (CBR; stable 
disease ≥3 months plus ORR). The safety population and pharmacodynamic parameters 
were summarized by dose group using descriptive statistics. Pharmacokinetic parameters 




From October 6, 2011 to April 21, 2014, 71 patients were enrolled from five centers 
in the USA, UK, and Spain (Table 1). In total, 24 patients were assigned to QD (six at 100 
mg, six at 150 mg, eight at 200 mg, and four at 300 mg), 27 to MWF (three patients each 
at 200, 300, 400 mg, and 600 mg, 12 at 900 mg, and three at 1,200 mg), and 20 to MTuW 
(three patients each at 200 mg, 400 mg, and 600 mg, and 11 patients at 900 mg) dosing. 
Sixty-one patients (86%) had PIK3CA-mutated tumors; the most common tumors 
were colorectal (25%) and breast (23%). Discontinuations before treatment completion (n 
= 69) were due to disease progression (n = 54), adverse events (AEs) (n = 9), subject 
decision (n = 4), or other reasons (n = 3). 
DLTs and MTD 
In total, 67 patients were DLT-evaluable: 24 QD, 25 MWF, and 18 MTuW patients. 
At data cut-off (September 14, 2015), cycle 1 DLTs, all grade 3 in severity, had occurred in 
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seven patients: two on the QD schedule (one at 200 mg: drug-induced hepatitis; one at 
300 mg: elevated alanine aminotransferase [ALT] and aspartate aminotransferase [AST]), 
four on the MWF schedule (two at 900 mg: one with ALT and AST elevation, one with 
hyperosmolar state; two at 1,200 mg: one with nausea, vomiting, diarrhea and 
hyperglycemia, one with decreased appetite), and one on MTuW dosing (at 900 mg: 
nausea). The MTD of TAK-117 for the QD schedule was 150 mg. For both intermittent 
schedules, the MTD was 900 mg. 
No patients in the 100 mg QD group and none of the initial three patients in the 200 
mg QD group reported DLTs. Dose was escalated to 300 mg QD and one of four patients 
experienced DLTs of grade 3 AST elevation and grade 3 ALT elevation from day 8, with 
resolution to grade 1 intensity within 2 to 11 days. Following dose de-escalation to 200 mg, 
an additional five patients were treated and one patient experienced a DLT of grade 3 
drug-induced hepatitis from day 25 to 28. All adverse events (AEs) resolved without 
sequelae. While tolerability of the 200-mg and 300-mg QD doses during cycle 1 were 
acceptable, AEs that occurred during cycles 2 and 3 resulted in dose interruptions and 
reductions. Thus, the dose was de-escalated to 150 mg, at which none of the six patients 
reported DLTs.  
As QD dosing resulted in dose-limiting transaminase elevations, intermittent dosing 
was evaluated in both MWF and MTuW schedules. On the MWF dosing schedule, no 
DLTs were reported in the 200, 300, 400, and 600 mg MWF groups. At 900 mg, among 
the initial 6 patients treated, one patient experienced a DLT of grade 3 AST elevation and 
grade 3 ALT evaluation from day 19 to 44. Dose was escalated to 1200 mg and two of the 
three patients had DLTs (all were grade 3): one patient experienced nausea, vomiting, 
diarrhea, and hyperglycemia; and one patient experienced grade 3 decreased appetite. 
Following dose de-escalation to 900 mg, an additional 6 patients were treated and one 
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patient experienced grade 3 hyperosmolar state from day 13 to 26. All AEs resolved 
without sequelae.  
There were no reports of DLTs in the 200, 400, and 600 mg MTuW groups. At 900 
mg, none of the initial three patients reported a DLT but one patient experienced a dose 
reduction to 600 mg. Of the next three patients who enrolled at 900 mg, one patient 
experienced a DLT of grade 3 nausea from days 8–22 and a subsequent dose reduction to 
600 mg; AE resolved without sequelae. Two of the five patients in the next enrollment for 
the 900 mg MTuW group experienced dose reduction to 600 mg. Dose escalation did not 
proceed in this schedule. 
Treatment exposure 
All 71 patients received at least one dose of TAK-117. Patients on the QD schedule 
received a median of 3 cycles (range 1–18); seven received ≥5 cycles. Those on the MWF 
schedule received a median of 3 cycles (range 1–15); nine patients received ≥5 cycles. In 
the MTuW arm, patients received a median of 3 cycles (range 1–27); four patients 
received ≥5 cycles. Median (range) treatment duration was 7.5 (1.0–53.1), 8.7 (0.7–44.7), 
and 7.4 (2.3–80.4) weeks on the QD, MWF, and MTuW schedules, respectively. 
Safety 
All patients reported at least one AE (most commonly nausea, vomiting, and 
fatigue; Tables 2 and 3), 89% of patients reported at least one drug-related AE (most 
commonly nausea, hyperglycemia, and vomiting), and 54% of patients reported at least 
one grade ≥3 AE (with drug-related grade ≥3 AEs in 27%). The most frequently observed 
grade ≥3 AEs were elevated liver transaminases (15% of patients) and hyperglycemia 
(8%); these were considered to be drug-related in 14% and 7% of patients, respectively 
(Table S1). Compared with QD dosing, intermittent dosing was associated with a lower 
incidence of grade ≥3 drug-related ALT/AST elevations (QD/MWF/MTuW, 21%/15%/5%), 
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but an increased incidence of grade ≥3 drug-related hyperglycemia (QD/MWF/MTuW, 
0%/7%/15%).  
Overall, serious AEs and discontinuations due to AEs were reported in 42% and 
13% of patients, respectively, and these were drug-related in 10% and 6% of patients. 
Three patients each in the QD and MWF dosing groups died within 30 days of the last 
dose of study drug, primarily due to disease progression or disease burden; no deaths 
were attributed to TAK-117. Further details of the safety profile of TAK-117 are provided in 
the Appendix. 
Pharmacokinetics and pharmacodynamics 
Among 69 pharmacokinetics-evaluable patients, TAK-117 exhibited moderately fast 
oral absorption with a median time to maximum observed plasma concentration of 1.5 to 6 
hours (Fig. 1A; Table S2). TAK-117 plasma exposures were generally dose-proportional 
over the 100–900 mg dose range albeit with a moderate-to-high inter-subject variability 
(%CV around AUCinf, 6.6–123). Based upon a preliminary power-model analysis to assess 
dose-linearity over the entire dose range (100–1,200 mg), the slope of the dose versus 
area under the plasma concentration–time curve from 0–24 hours (AUC0-24h) was 0.871 
(95% confidence interval [CI], 0.627–1.115), suggesting that TAK-117 exhibits a slightly 
less than dose-proportional increase in exposures over the entire dose range (Fig. 1B).  
The mean terminal half-life of TAK-117 was ~11 hours (range, 6–14 hours). There 
was no meaningful accumulation of TAK-117 with repeated dosing for any schedule (Table 
S3). Intermittent schedules achieved higher total weekly doses and exposures of TAK-117. 
In previously tested preclinical tumor models and dose-ranges, TAK-117 antitumor activity 
correlated linearly with plasma exposures and no evidence of an exposure threshold for 
efficacy was observed (17, 18). Based upon a preliminary pharmacokinetic model that 
simulated various dosing scenarios (Fig. 1C), compared to QD dosing, intermittent dosing 
schedules were predicted to achieve higher total weekly exposures of TAK-117 and a 
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longer duration above pharmacologically active thresholds based upon nonclinical 
exposure–antitumor response evaluation. The total weekly doses were 1,050 mg at an 
MTD of 150 mg QD and 2,700 mg at the recommended phase II dose of 900 mg MWF or 
MTuW. These doses were predicted to provide total weekly area under the curve at steady 
state (AUCss) values of ~105,000 ng*hour/mL for QD dosing and ~470,000 ng*hour/mL for 
the intermittent schedules. Dosing with the QD schedule resulted in ALT/AST elevations 
and prompted the evaluation of an alternative intermittent dosing schedule. The prediction 
of higher total weekly exposures with intermittent dosing was confirmed following 
completion of the 900 mg MTuW and MWF cohorts (Table S2). The administration of TAK-
117 via the intermittent dosing schedule more than doubled the weekly dose and achieved 
higher weekly total exposures (maximize AUCss) than the QD schedule. In addition, based 
upon the pharmacokinetic model predictions, the duration above the preclinically estimated 
desirable average plasma concentration (Cavg) for QD dosing was approximately 16 
hours/week versus approximately 75 hours/week for the two intermittent dosing schedules.  
Sixty patients had sufficient skin samples for pharmacodynamic evaluation. TAK-
117 at doses between 200 and 900 mg suppressed pS6 expression to varying degrees in 
skin biopsies (Fig. 2A). Of five paired tumor samples examined, a TAK-117-induced 
reduction in pS6 expression was seen in tumor biopsies taken from two patients on the 
200 mg MWF/MTuW schedules (Fig. 2B).  
Antitumor activity  
Among 61 response-evaluable patients (QD, n = 20; MWF, n = 25; MTuW, n = 16), 
53 patients had tumors with PIK3CA mutation. Four patients (all PIK3CA mutants) 
achieved a PR, three with breast cancer and one with gastric cancer (Fig. 3). The median 
duration of PR was 7 months (range, 3.6–12.2 months). Twenty-seven out of 61 patients 
(44%) were assessed by investigators to have stable disease. Seventeen patients (28%; 
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all PIK3CA mutants) had stable disease lasting ≥3 months. CBR was 34%; rates (40%, 
32%, 31%) and median durations of clinical benefit (4.8, 4.8, 5.3 months) were 
comparable between the QD, MWF, and MTuW schedules, respectively.  
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Discussion 
TAK-117 has demonstrated preclinical antitumor activity in tumor cell lines and 
xenograft models of human solid tumors bearing PIK3CA mutations (16). In this study of 
71 patients with advanced solid tumors who had received prior treatments (86% of whom 
were PIK3CA mutated), three different dose schedules of TAK-117 were evaluated. The 
MTD of TAK-117 was established as 150 mg QD and 900 mg for both intermittent 
(MWF/MTuW) schedules.  
The safety profile of TAK-117 was acceptable and consistent with profiles reported 
for other small-molecule PI3K inhibitors (10, 12, 13, 21-25). Drug-related grade ≥3 AEs 
occurred in 27% of patients, and discontinuations due to all-cause AEs in 13%. Common 
AEs included gastrointestinal and constitutional toxicities, along with changes in liver 
transaminases and blood glucose elevation, both of which were transient in nature. 
Although TAK-117 administration resulted in hyperglycemia, a known side effect of 
PI3K inhibition (10, 12, 13, 21, 22, 24, 25), the rate of drug-related grade ≥3 hyperglycemia 
(7% of patients overall; 3% of patients receiving 150 mg QD or 900 mg intermittently) 
observed with TAK-117 was generally lower than rates previously reported with other PI3K 
inhibitors. Grade ≥3 hyperglycemia occurred more frequently in patients on the intermittent 
schedules (MWF, 7%; MTuW, 15%) versus QD dosing (0%). This higher rate of severe 
hyperglycemia with intermittently administered TAK-117 may reflect the higher weekly 
dose and exposure achieved relative to QD dosing. TAK-117-related grade ≥3 rash was 
not reported in the present study. In comparison, grade ≥3 rash occurred in 8% of patients 
who received continuous daily pictilisib (15 to 450 mg), including two DLTs at the 450 mg 
dose level (12). Grade ≥3 rash was also previously reported in 7% patients who received 
continuous daily buparsilib (24). Furthermore, TAK-117 was not associated with mood 
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alterations, as reported with buparlisib (21, 22). Further studies are required to fully assess 
the safety profile of TAK-117 relative to other pan-PI3K or selective PI3Kɑ inhibitors.  
Preliminary pharmacokinetic simulations predicted that, compared with QD dosing 
at 150 mg, intermittent dosing (MTuW or MWF) at the MTD of 900 mg would achieve 
higher total weekly plasma exposures of TAK-117 and longer durations over which the 
Cavg would exceed the desirable pharmacologically active concentrations predicted from 
preclinical data. Patients treated with the QD schedule (150 mg MTD; weekly total dose of 
1050 mg) demonstrated an increased rate of ALT/AST elevations and dose 
modifications/interruptions, thus prompting evaluation of alternative schedules to dose 
escalate and maximize AUC. Intermittent dosing at 900 mg (total weekly dose of 2700 mg) 
allowed  a larger dose of TAK-117 to be administered to achieve higher total weekly 
exposures with improved tolerability, without increasing toxicity with the exception of grade 
≥3 hyperglycemia. Preclinical xenograft studies of TAK-117 suggested that its inhibitory 
effect on tumor growth is dependent on total systemic exposure levels, regardless of 
whether TAK-117 is given via continuous or intermittent dosing (17, 18). Furthermore, 
pharmacodynamic analysis in the present study indicated that the systemic exposures 
seen with intermittent dosing at 200–900 mg resulted in PI3K pathway modulation as 
evidenced by suppression of pS6 expression, thus confirming the on-target activity and 
dose range required for clinical response. Based on these data, intermittent dosing of 
TAK-117 (900 mg MTuW) has been taken forward into new trials.  
Pharmacokinetics analysis demonstrated that the mean terminal half-life of TAK-
117 ranged from 6 to 14 hours, and that there was no meaningful plasma accumulation of 
TAK-117 following repeated dosing in any of the dosing schedules. Earlier studies of other 
PI3K inhibitors (pan-PI3K and PI3Kα-specific) have mostly used QD schedules with the 
assumption that continuous suppression of the PI3K pathway is required for antitumor 
effects in PIK3CA-mutated tumors (12, 21-24). However, a recent report showed that 
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pulsatile administration (three times per week) of copanlisib increased the suppression of 
tumor growth compared with continuous dosing in a PIK3CA-mutated breast cancer 
model. The authors concluded that intermittent target inhibition may allow adequate 
inhibition of the PI3K pathway without causing excessive toxicity or chronic feedback 
reactivation of upstream receptors (26). Therefore, evaluation of clinical efficacy of the 
intermittent versus continuous dosing schedules of PI3K inhibition is warranted. 
Furthermore, intermittent dosing could potentially provide a better safety and tolerability 
profile, needed for dose durability and maintenance of patients on treatment. 
Antitumor activity was observed with TAK-117 (4 PRs in 67 response-evaluable 
patients), but its single-agent efficacy was limited. Despite the higher exposure levels 
achieved with intermittent schedules, both CBRs (40%, 32%, and 31%) and median 
durations (4.8, 4.8, and 5.3 months) were comparable between the QD, MWF, and MTuW 
dosing groups. Although tumor types were diverse, the majority (86%) were confirmed to 
carry PIK3CA mutations. Assessment of PIK3CA mutation status before study enrollment 
was done by non-standardized, local testing. Blood-based assays have become available 
since this study was devised, and the use of such methods would enable improved 
assessments if the study were re-created today. The antitumor activity we observed with 
TAK-117 is in line with that of other PI3K inhibitors tested in similar patient populations. 
For example, daily dosing of single-agent buparlisib (12.5–150 mg) in 83 patients yielded 
one confirmed PR and a disease control rate of 41% (24). Similarly, PX-866 achieved 
stable disease in 22% and 53% of patients on intermittent (days 1 to 5 and 8 to 12 of a 28-
day cycle) and QD dosing schedules, respectively (23).  
It is possible that continuous PI3K pathway suppression (via daily dosing or 
pulsatile dosing with a tightly controlled off-time) is needed for clinical efficacy in tumors 
carrying PIK3CA mutations, where these activating mutations may function as a driver 
event in tumorigenesis. However, the requirement for PI3K target inhibition may be 
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significantly different in a combination setting. Activation of the PI3K pathway in tumor cells 
may represent a compensatory survival mechanism in response to chemotherapy (27-29). 
Synergistic antitumor activity has been reported with PI3K inhibition in combination with 
treatments such as CDK 4/6 inhibition or antagonism of EGFR and HER3 (30, 31). The 
potential for combining PI3K inhibition with other therapies has also been acknowledged 
(32, 33) particularly in the context of prostate, breast, and ovarian cancer (27, 29, 34). An 
ongoing phase I/II trial plans will investigate the efficacy, safety, and tolerability of 
docetaxel with or without TAK-117 in patients with locally advanced or metastatic 
squamous or non-squamous non-small cell lung cancer (clinicaltrials.gov: NCT02393209). 
The MTuW schedule of TAK-117 will be used with the expectation that a high-dose, 
intermittent schedule would be more effective than QD dosing in blocking the adaptive 
response to chemotherapy insult.  
In conclusion, the results of this study suggested that the safety profile of TAK-117 
is acceptable and manageable. Intermittent dosing schedules achieved higher total weekly 
doses and exposures compared with QD dosing, generally without increasing toxicity. 
Although single-agent activity was limited, early signs of antitumor activity were observed 
and the CBR was encouraging. Our results support intermittent rather than continuous 
dosing of TAK-117, suggesting use of the drug in combination with other therapies for 
advanced tumors. PI3K inhibition is expected to block an adaptive survival mechanism to 
chemotherapy or other stress-inducing agents.
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Tables 
Table 1. Patient characteristics and baseline demographics 
Characteristic 
Total 
N = 71 
TAK-117 QD 
100–300 mg 
n = 24 
TAK-117 
MWF 200–
1,200 mg  
n = 27 
TAK-117 MTuW
200–900 mg  
n = 20 










Gender male:female, % 31:69 33:67 22:78 40:60 
Race, n (%) 
 
   
White 65 (92) 23 (96) 24 (89) 18 (90) 
Black/African American 2 (3) 0 1 (4) 1 (5) 
Asian 3 (4) 1 (4) 1 (4) 1 (5) 
Other/not reported 1 (1) 0 1 (4) 0 
PIK3CA mutation, n (%) 
 
   
Positive 61 (86) 21 (88) 24 (89) 16 (80) 
Wild-type 8 (11) 2 (8) 2 (7) 4 (20) 
Unknown 2 (3) 1 (4) 1 (4) 0 











Tumor type, n (%)     
Colorectal 18 (25) 7 (29) 6 (22) 5 (25) 
Breast 16 (23) 9 (38) 5 (19) 2 (10) 
Ovarian 9 (13) 0 7 (26) 2 (10) 
Lung 6 (8) 2 (8) 1 (4) 3 (15) 
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Head and neck 5 (7) 2 (8) 1 (4) 2 (10) 
Gastric 2 (3) 2 (8) 0 0 
Endometrial 3 (4) 0 2 (7) 1 (5) 
Prostate 1 (1) 0 0 1 (5) 
Renal 1 (1) 1 (4) 0 0 
Other* 10 (14) 1 (4) 5 (19) 4 (20) 
Median time since initial 









*Includes squamous cell carcinoma, cervical cancer, squamous cell carcinoma of the 
tonsil, ocular melanoma, adenoid cystic carcinoma of the hard palate, metastatic poorly 
differentiated transitional cell carcinoma of the bladder, serous carcinoma of fallopian tube, 
cervical squamous cell carcinoma, transitional cell carcinoma of the bladder, and penile 
carcinoma (n = 1 each).  
MTuW, Monday-Tuesday-Wednesday; MWF, Monday-Wednesday-Friday; QD, once daily. 
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Table 2. Summary of safety profiles of TAK-117 by dosing schedule 
AE, n (%) 
Total 
N = 71 
TAK-117 QD 
100 to 300 mg 
n = 24 
TAK-117 MWF 
200 to 1,200 mg 
n = 27 
TAK-117 MTuW 
200 to 900 mg 


















71 (100) 63 (89) 24 
(100) 
21 (88) 27 
(100) 
24 (89) 20 
(100) 
18 (90) 
Grade ≥3 38 (54) 19 (27) 13 (54) 6 (25) 12 (44) 6 (22) 13 (65) 7 (35) 
SAE 30 (42) 7 (10) 11 (46) 2 (8) 11 (41) 3 (11) 8 (40) 2 (10) 
Discontinuations 
due to AEs 
9 (13) 
 
4 (6) 4 (17) 
 
1 (4) 2 (7) 
 










20 (28) 11 (46)
 
 
5 (21) 9 (33) 
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*Within 30 days of last dose of study drug. 








ber 1, 2017. © 2017 Am











ay 10, 2017; DO
I: 10.1158/1078-0432.CCR-16-2888 
Phase I trial of the PI3Kα isoform inhibitor TAK-117 
Juric CCR-16-2888 Manuscript Revisions – 30 
Table 3. Summary of most common any cause AEs by dosing schedule (any grade in 
≥20% and grade ≥3 in ≥5% of patients overall) 
AE, n (%) 
Total 
N = 71 
TAK-117 QD 
100 to 300 mg 
n = 24 
TAK-117 MWF 
200 to 1,200 
mg 
n = 27 
TAK-117 
MTuW 
200 to 900 mg

















Nausea 43 (61) 3 (4) 14 (58) 1 (4) 15 (56) 1 (4) 14 (70) 1 (5) 
Vomiting 36 (51) 2 (3) 8 (33) 1 (4) 16 (59) 1 (4) 12 (60) 0 
Fatigue 34 (48) 3 (4) 12 (50) 1 (4) 12 (44) 1 (4) 10 (50) 1 (5) 
Diarrhea 33 (46) 2 (3) 12 (50) 0 12 (44) 1 (4) 9 (45) 1 (5) 
Hyperglycemia 26 (37) 6 (8) 7 (29) 0 10 (37) 2 (7) 9 (45) 4 (20) 
Decreased 
appetite 
24 (34) 2 (3) 8 (33) 0 10 (37) 1 (4) 6 (30) 1 (5) 
Constipation 25 (35) 0 9 (38) 0 9 (33) 0 7 (35) 0 
Elevated AST 24 (34) 5 (7) 10 (42) 3 (13) 10 (37) 2 (7) 4 (20) 0 
Elevated ALT 19 (27) 6 (8) 9 (38) 3 (13) 7 (26) 2 (7) 3 (15) 1 (5) 
Anemia 15 (21) 2 (3) 4 (17) 0 9 (33) 2 (7) 2 (10) 0 
Cough 14 (20) 0 5 (21) 0 6 (22) 0 3 (15) 0 
Hypokalemia 14 (20) 1 (1) 3 (13) 0 7 (26) 0 4 (20) 1 (5) 
Respiratory 
failure 
4 (6) 4 (6) 1 (4) 1 (4) 3 (11) 3 (11) 0 0 
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AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
MTuW, Monday-Tuesday-Wednesday; MWF, Monday-Wednesday-Friday; QD, once daily; 
SAE, serious adverse event. 
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FIGURE LEGENDS 
Figure 1. Pharmacokinetic analyses of TAK-117: (A) mean TAK-117 plasma 
concentration–time profile by dose level on day 1 of cycle 1; (B) dose-proportionality plot of 
TAK-117 dose versus AUC0-24h; and (C) simulated TAK-117 plasma concentration–time 
profiles over a dosing week for the QD and intermittent dosing schedules. AUC0-24h, area 
under the TAK-117 plasma concentration–time curve from 0–24 hours; Cavg, average TAK-
117 plasma concentration; CI, confidence interval; MTuW, Monday-Tuesday-Wednesday; 
MWF, Monday-Wednesday-Friday; QD, once daily. 
 
Figure 2. Pharmacodynamic effects of TAK-117: (A) Box-and-whisker plot showing 
changes from baseline in pS6 expression in skin biopsies (boxes, interquartile distance 
[Q1–Q3]; bars, median; whiskers, 10th and 90th percentiles; circles, observations outside 
90% distribution interval); and (B) representative images of tumor biopsies from patients 
dosed at 200 mg on the intermittent schedules showing decreased pS6 expression 
(indicated by the immunohistochemistry H-score provided below each image). 
MTuW, Monday-Tuesday-Wednesday; MWF, Monday-Wednesday-Friday. Bar equals 200 
mM. 
 
Figure 3. Treatment duration and response in patients treated with TAK-117 100–1200 
mg. 
CBR, clinical benefit rate; Med Dur, median duration of clinical benefit; MTuW, Monday-
Tuesday-Wednesday; MWF, Monday-Wednesday-Friday; NSCLC, non-small cell lung 
cancer; PD, progressive disease; PR, partial response; QD, once daily; SD, stable 
disease. 
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